Sure.
My colleague, Ian, referred to it somewhat regarding speeding up the approval process. Right now, we look at that two- to three-year period. If we want to make Canada a leader in biotech and in investment, we should be able to drive that down to a one-year period. There's no cost to the government for that. That's simply a matter of applying better principles and speeding up the process.
On funding, it's making sure that those regulatory agencies are fully staffed, so they can deal with not only the technical requirements, but also a lot of trade issues that are now involved. For example, the Pest Management Regulatory Agency not only deals with health and safety issues, but they also end up dealing with issues of what's called MRL, maximum residue limits, that have impacts on trade. Are those regulatory agencies staffed well enough to provide the resources that are going to be required? That would be the funding issue that would come up for us.
However, the reform of the regulatory system—and my colleague, Ian, could speak to that more fully—is something that we're pushing because we want to make Canada a centre for that investment in biotech. We know that research is going to take place. It's going to take place somewhere in the world. We'd like it to take place in Canada.